Anti-inflammatory effect of different PRGF formulations on cutaneous surface

Area of Science:

• Dermatology and Regenerative Medicine
• Biotechnology and Biomedical Engineering

Background:

• Cutaneous autoimmune and inflammatory diseases pose a significant global health burden with limited effective treatments.
• The heterogeneity and multifactorial nature of these conditions necessitate novel therapeutic approaches.
• Plasma rich in growth factors (PRGF) technology presents a potential alternative for managing skin inflammation.

Purpose of the Study:

• To evaluate the efficacy of two PRGF formulations (activated PRGF and autologous topical serum - ATS) in managing skin inflammation.
• To assess the impact of ATS on patients with radiotherapy-induced dermatitis.
• To investigate the effects of PRGF and ATS on human organotypic skin explant cultures (hOSECs) under atopic dermatitis-like conditions.

Main Methods:

• Human organotypic skin explant cultures (hOSECs) were utilized as a human skin model.
• Atopic dermatitis-like conditions were induced using interleukin-4 (IL-4) and interleukin-13 (IL-13).
• PRGF and ATS were applied intradermally and topically, respectively, with subsequent analysis of metabolic activity, reactive oxygen species (ROS), necrosis, and inflammatory cytokine production.

Main Results:

• Both PRGF formulations enhanced tissue viability and significantly reduced reactive oxygen species (ROS) and inflammatory cytokine production (TNF-α, IL-1β).
• Autologous topical serum (ATS) treatment in case reports led to improved skin quality, reduced erythema, and alleviation of burning and itching.
• ATS also reduced edema, swelling, and desquamation in patients with radiation-induced dermatitis, with reported cessation of pruritus and pain.

Conclusions:

• PRGF formulations demonstrate potential as an adjunct therapy for inflammatory skin conditions.
• ATS shows promise in improving skin quality and alleviating symptoms associated with inflammatory dermatoses and radiation dermatitis.
• Further clinical investigation is warranted to confirm the therapeutic benefits of PRGF and ATS in managing cutaneous inflammatory diseases.